Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): A phase 3 randomised controlled trial

The Lancet Oncology

Volumn 13, Issue 12, 2012, Pages 1225-1233

  de Gramont, Aimery ^a   Van Cutsem, Eric ^b   Schmoll, Hans Joachim ^c   Tabernero, Josep ^d   Clarke, Stephen ^e   Moore, Malcolm J ^f   Cunningham, David ^g   Cartwright, Thomas H ^h   Hecht, J Randolph ⁱ   Rivera, Fernando ^j   Im, Seock Ah ^k   Bodoky, György ^l   Salazar, Ramon ^m   Maindrault Goebel, Frédérique ^a   Shacham Shmueli, Einat ⁿ   Bajetta, Emilio ^o   Makrutzki, Martina ^p   Shang, Aijing ^p   André, Thierry ^a   Hoff, Paulo M ^q  

^a HÔPITAL SAINT ANTOINE   (France)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c University Clinic Halle (Saale)   (Germany)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF TORONTO   (Canada)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h Ocala Oncology   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^k Seoul National University Hospital   (South Korea)

^l Szent Laszlo Hospital   (Hungary)

^m CATALAN INSTITUTE OF ONCOLOGY   (Spain)

ⁿ TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^o Istituto di Oncologia Policlinico di Monza   (Italy)

^p F HOFFMANN LA ROCHE LTD   (Switzerland)

^q UNIVERSITY OF SÃO PAULO   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ABSCESS; ADULT; AGED; ARTERY THROMBOEMBOLISM; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; COLON CARCINOMA; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG FATALITY; DRUG SAFETY; FEMALE; FISTULA; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; VENOUS THROMBOEMBOLISM; VOMITING; WOUND HEALING IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; YOUNG ADULT;

EID: 84870244259     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70509-0     Document Type: Article

References (37)

1. Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009, 27:872-877.
2. André T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 2007, 20:3732-3738.
3. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005, 352:2696-2704.
4. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351.
5. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
6. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343:905-914.
7. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000, 355:1041-1047.
8. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990, 322:352-358.
9. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995, 345:939-944. International Multicentre Pooled Analysis of Colorectal Cancer Trials (IMPACT).
10. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999, 17:3553-3559.
11. André T, Colin P, Louvet C, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003, 21:2896-2903.
12. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007, 25:2198-2204.
13. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011, 29:1465-1471.
14. Ferrara N, Davis-Smyth T The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25.
15. Willett CG, Boucher Y, Di Tomaso E, et al. Direct evidence that the VEGF specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145-147.
16. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
17. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
18. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23:3706-3712.
19. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011, 29:11-16.
20. Marcus R, Peritz E Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1975, 63:655-660.
21. Kerbel RS Tumor angiogenesis. N Engl J Med 2008, 358:2039-2049.
22. Norton L Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist 2005, 10:370-381.
23. Bergers G, Hanahan D Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
24. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
25. Ebos JM, Lee CR, Kerbel RS Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009, 15:5020-5025.
26. Miles D, Harbeck N, Escudier B, et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2011, 29:83-88.
27. Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008, 27:3944-3956.
28. Jain A, Penuel E, Mink S, et al. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res 2010, 70:1989-1999.
29. Rasheed ZA, Rubin EH Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 2003, 22:7296-7304.
30. Folkman J, Watson K, Ingber D, Hanahan D Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339:58-61.
31. Almog N Molecular mechanisms underlying tumor dormancy. Cancer Lett 2010, 294:139-146.
32. Naumov GN, Townson JL, MacDonald IC, et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 2003, 82:199-206.
33. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007, 25:3456-3461.
34. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009, 27:3117-3125.
35. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 60:1408-1417.
36. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012, 307:1383-1393.
37. Taieb J, Tabernero J, Mini E, et al. Adjuvant FOLFOX4 with or without cetuximab (ctx) in patients (pts) with resected stage III colon cancer (cc): DFS and overall survival results and subgroup analyses of the PETACC8 Intergroup phase III trial. Ann Oncol 2012, 23(suppl 9). abstr #LBA4.